CAS: 94055-76-2; (3-((4-(3-Ethoxy-2-Hydroxypropoxy)Phenyl)Amino)-3-Oxopropyl)Dimethylsulfonium 4-Methylbenzenesulfonate

该化合物是一种抗脊髓灰质炎和免疫性循环剂,主要用于治疗哮喘和过敏性鼻炎等过敏性疾病,其作用是抑制某些细胞皮素的生产,调节免疫反应,从而减少炎症和过敏性症状;该化合物的特征是能够阻塞作为过敏反应关键人物的Interleukin-4和Interleukin-13的动作; 血压托菌一般是口服的,已知其副作用相对较低; 其化学结构包括一个相片状体,有助于其药性特性; 该物质一般具有良好的发酵作用,但与任何药物一样,它可能与其他药物有抵触和潜在相互作用; 研究继续探索其在各种过敏和自成膜条件下的功效和安全,使其成为药理研究的一个主题.

结构式图片

欧盟法规

ECHA物质C&L通报

上下游产品

CAS号100-02-7 对硝基苯酚 | CAS号94925-71-0 2-Propanol, 1-e... | CAS号94056-98-1 4-(3-乙氧基-2-羟基丙氧基)苯胺 | CAS号80-48-8 对甲苯磺酸甲酯 | CAS号160114-16-9 2-{4-(3-ethoxy-...

合成工艺路线路线简述

  • 合成目标产物 Suplatast Tosilate 主要起始原料 4-Aminophenol
  • (文献来源)合成步骤主要原料 4-Aminophenol
2-[(4-硝基苯氧基)甲基]环氧乙烷置于palladium On Activated Charcoal 硫酸,氢气,三乙胺体系中,用 乙醇,二氯甲烷 作为反应溶剂,化学反应 137.0H,反应生成 甲磺司特
参考文献:Synthesis And Antiallergic Activity Of Dimethyl-2-(Phenylcarbamoyl)Ethylsulfonium P-Toluenesulfonate Derivatives
标题:Synthesis And Antiallergic Activity Of Dimethyl-2-(Phenylcarbamoyl)Ethylsulfonium P-Toluenesulfonate Derivatives
摘要:The Derivatives Of Dimethyl-2-(Phenylcarbamoyl)Ethylsulfonium P-Toluenesulfonates Were Synthesized And Evaluated For Antiallergic Activity. The 2,3-Dihydroxyethoxy Group Was Introduced To The Phenyl Ring From The Standpoint Of Lipophilicity And Electronic Effects Of Substituent. The Ige-Induced Rat Passive Cutaneous Anaphylaxis (Pca) Was Inhibited By Oral Administration Of Several Substituted 2-[(4-Propoxyphenyl)Carbamoyl]Ethyldimethylsulfonium P-Toluenesulfonate Derivatives. Among Them (+/-)-2-[4-(3-Ethoxy-2-Hydroxypropoxy)Phenyl]-Carbamoyl]Ethyldimethylsulfonium P-Toluenesulfonate (1A,Ipd-1151T) Was Found To Possess Considerable Activity In The Pca Test,And It Was Launched As Suplatast Tosilate In Japan.
DOI:10.1021/jm970285Z

海关参考信息

专利信息


专利号:US-10906888-B2
优先权日:2016-07-14
标 题:Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme
发明人:CASIMIRO-GARCIA AGUSTIN; STROHBACH JOSEPH WALTER; HEPWORTH DAVID; LOVERING FRANK ELDRIDGE; CHOI CHULHO; ALLAIS CHRISTOPHE PHILIPPE; WRIGHT STEPHEN WAYNE
权利人:PFIZER
摘要:Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

专利号:US-10308615-B2
优先权日:2015-05-29
标 题:Heterocyclic compounds as inhibitors of Vanin-1 enzyme
发明人:CASIMIRO-GARCIA AGUSTIN; CONDON JEFFREY SCOTT; FLICK ANDREW CHRISTOPHER; GOPALSAMY ARIAMALA; KIRINCICH STEVEN J; MATHIAS JOHN PAUL; STROBACH JOSEPH WALTER; XIANG JASON SHAOYUN; XING LI HUANG; WANG XIAOLUN
权利人:PFIZER
摘要:Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

专利号:US-2018230127-A1
优先权日:2015-08-13
标题 :Bicyclic-Fused Heteroaryl Or Aryl Compounds
发明人:ANDERSON DAVID RANDOLPH; CURRAN KEVIN JOSEPH; GAVRIN LORI KRIM; GOLDBERG JOEL ADAM; LEE ARTHUR; LOWE MICHAEL DENNIS; PATNY AKSHAY; PIERCE BETSY SUSAN; SAIAH EDDINE; TRZUPEK JOHN DAVID
权利人:PFIZER
摘要:Compounds, tautomers and pharmaceutically acceptable salts of the compounds of Formula (Ia) are disclosed which are inhibitors of Interleukin-1 receptor associated kinase (IRAK4). Methods of treatment, methods of synthesis, and intermediates are also disclosed as defined in the specification.

专利号:US-10316018-B2
优先权日:2015-08-27
标题 :Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators
发明人:LEE KATHERINE LIN; ALLAIS CHRISTOPHE PHILIPPE; DEHNHARDT CHRISTOPH MARTIN; GAVRIN LORI KRIM; HAN SEUNGIL; HEPWORTH DAVID; LEE ARTHUR; LOVERING FRANK ELDRIDGE; MATHIAS JOHN PAUL; OWEN DAFYDD RHYS; PAPAIOANNOU NIKOLAOS; SAIAH EDDINE; STROHBACH JOSEPH WALTER; TRZUPEK JOHN DAVID; WRIGHT STEPHEN WAYNE; ZAPF CHRISTOPH WOLFGANG
权利人:PFIZER
摘要:Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
沈阳海诺威医药科技有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.hinewy.com
企业联系电话:13709882332,13358863169;024-31682991👤
📞沈阳海诺威医药科技有限公司 ⚠️参考联系方式
联系人:董女士;董经理
电话:13709882332,13358863169;024-31682991
手机:13709882332;13358863169
传真:QQ:65860507
邮箱:Sales-hinewy@hinewy.com
通信地址: 沈阳市沈河区大南街勒石里11-1号 2-2-1
邮编: 110000
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:沈阳市沈河区大南街勒石里11-1号 2-2-1
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
海口恒康达化工有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.hkdchem.com
电话: 0086 (898) 3198-9500👤
📞海口恒康达化工有限公司 ⚠️参考联系方式

销售电话:0086 (898) 3198-9500
邮箱:hkd@hkdchem.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Mizuguchi H, Orimoto N, Kadota T, Kominami T, Das AK, Sawada A, Tamada M, Miyagi K, Adachi T, Matsumoto M, Kosaka T, Kitamura Y, Takeda N, Fukui H. Suplatast tosilate alleviates nasal symptoms through the suppression of nuclear factor of activated T-cells-mediated IL-9 gene expression in toluene-2,4-diisocyanate-sensitized rats. J Pharmacol Sci. 2016 Mar;130(3):151-8. doi: 10.1016/j.jphs.2015.12.008. Epub 2016 Jan 6. doi: 10.1684/ejd.2015.2687. doi: 10.1111/pde.12552. Epub 2015 Mar 17. doi: 10.1159/000369977. Epub 2015 Jan 13. Japanese. Chinese. doi: 10.1684/ejd.2014.2274. doi: 10.2332/allergolint.13-OA-0583. Epub 2014 Feb 25. doi: 10.1016/j.ijpharm.2013.10.049. Epub 2013 Nov 6. doi: 10.231/JIM.0000000000000012. doi: 10.3892/mmr.2013.1485. Epub 2013 May 20. Epub 2012 Sep 11.
13: Shiga M, Horiguchi T, Kondo R, Miyazaki J, Hirose M, Otake Y, Hata H, Tachikawa S. Long-term monotherapy with suplatast tosilate in patients with mild atopic asthma: a pilot comparison with low-dose inhaled fluticasone. Asian Pac J Allergy Immunol. 2011 Jun;29(2):134-42. doi: 10.1684/ejd.2011.1539. doi: 10.1055/s-0031-1296221. doi: 10.1111/j.1346-8138.2010.00990.x. Epub 2010 Sep 28. doi: 10.2147/IMCRJ.S26102. Print 2011.
18: Matsui E, Shinoda S, Fukutomi O, Kaneko H, Fukao T, Kondo N. Relationship between the benefits of suplatast tosilate, a Th2 cytokine inhibitor, and gene polymorphisms in children with bronchial asthma. Exp Ther Med. 2010 Nov;1(6):977-982. Epub 2010 Sep 15.

合成参考文献


摘要:Iyakuhin Kenkyu. Study of Medical Supplies., 26(239), 1995
摘要:Yamasawa H, Oshikawa K, Sugiyama Y. [Cytokine production by peripheral blood mononuclear cells in bronchial asthma treated with suplatast tosilate]. Arerugi. 2001 Jun;50(6):513–9.
摘要:Mir MA, Khalil F. Case 36-2007: a woman with rash, fever, and hypotension. N Engl J Med. 2008 Mar 27;358(13):1406; author reply 1406–7.
参考文献:10.1016/s0014-2999(96)00810-2
摘要:Taniguchi H, Togawa M, Ohwada K, Kiniwa M, Matsuura N, Nagai H, Koda A. Suplatast tosilate, a new type of antiallergic agent, prevents the expression of airway hyperresponsiveness in guinea pigs. Eur J Pharmacol. 1996 Dec 30;318(2-3):447–54. doi: 10.1016/s0014-2999(96)00810-2.
参考文献:10.3109/08820130903496769
摘要:Bae SJ, Lee JB, Shimizu K, Kuwazuka Y. Increase effect of transforming growth factor on eotaxin production by normal cultured dermal fibroblasts stimulated with interleukin-4: inhibitory effect of suplatast tosilate on eotaxin production. Immunol Invest. 2010 Jan;39(2):93–102. doi: 10.3109/08820130903496769.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知